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Abstract 
 Human immunodeficiency virus, also referred to as HIV, is a devastating virus which has 
infected millions. Characterized as a retrovirus, HIV has an RNA genome, which is reverse 
transcribed into DNA upon entry into the host cell. HIV primarily affects CD4+ T cells and is 
diagnosed by the significant reduction of CD4+ T cells. While no cure has been discovered yet, 
antiretroviral therapy (ART) has been demonstrated as an effective treatment option. In the 
progression of HIV, additional HIV-associated diseases may arise, including HIV-associated 
psoriasis and sensory neuropathy. In addition to the use of ART, clinicians often prescribe 
opioids to manage the chronic pain experienced by patients with HIV. However, studies have 
demonstrated the immunosuppressant properties of opioids, which enhance HIV infection and 
must therefore be taken into consideration in the treatment of HIV. 
Keywords: human immunodeficiency virus, HIV, antiretroviral therapy, immunosuppression, 
sub-Saharan Africa, opioid management 
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Introduction 
Human immunodeficiency virus (HIV) is a devastating disease that has infected millions 
worldwide and has induced high mortality rates. Tragically, 37.9 million people were infected 
with HIV in 2018, 1.7 million of whom were children under 15 years old. While HIV may 
present in individuals as HIV-1 or HIV-2, HIV-1 is more commonly diagnosed. Since its 
discovery in the early 1980s, HIV has been extensively researched to uncover the underlying 
molecular mechanisms of this disease. While the discovery of a definitive cure has progressed 
slowly, the spread of this virus has increased rapidly. Progress on the treatment includes first, a 
comprehensive understanding of the pathophysiology of HIV, with emphasis on the viral 
structure, modes of entry, and primary infection of T cells, second, an investigation of the role of 
opioids in immunosuppression and subsequent enhancement of HIV infection and third, an 
examination of the role of clinicians in treating HIV patients, especially those at risk for opioid 
abuse. 
Epidemiology 
  While many cases arise each year in the United States, HIV is most prevalent in sub-
Saharan Africa,  where 85% of HIV cases exist (Williams et al., 2017). In more economically 
disadvantaged areas, treatment options may be scarce, significantly affecting the infected 
individual’s chance of survival. Such is true in areas like sub-Saharan Africa, where a study 
conducted in 2015 revealed that 6.5 to 19 million people were infected with HIV, and 330, 000 
to 470, 000 people experienced HIV-related deaths (Nansseu and Bigna,2017). These statistics 
demonstrate the need for increased accessibility to antiretroviral therapy and production of more 
cost-effective versions of antiretroviral therapy (ART) (Zulfiqar et al., 2017). 
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Pathophysiology 
HIV-1 and HIV-2 
 Infection may be caused by type 1 or type 2 HIV. Though they are distinct from one 
another, both share certain biological and genetic characteristics. HIV-1 is thought to have 
originated from the simian immunodeficiency virus (SIV), which infected African chimpanzees, 
while HIV-2 may have originated from SIV-infecting sooty mangabeys (Owen et al., 2013). 
Interestingly, while HIV-1 infections are global, HIV-2 infections are found primarily in West 
Africa, parts of India, and some former Portuguese colonies including Angola, Mozambique, and 
Brazil (Vidya Vijayan et al., 2017). Due to the global prevalence of HIV-1, primarily the 
specifics of this strain will be examined. 
HIV-1 Structure 
 Analysis of the viral genome has revealed key structures that aid in the infection of host 
cells. Within the genome, three genes code for structural features, while six additional genes 
code for accessory and regulatory enzymes (See Figure 1) (Owen et al., 2013). Encoded by the 
ENV gene, the HIV-1 envelope glycoprotein is the receptor that binds to CD4+ on host T helper 
cells and facilitates subsequent fusion with CD4+ T cells. Proteolytic cleavage or dissociation of 
the trimeric glycoprotein forms gp120 and gp41 heterodimers, which are crucial for proper 
attachment and fusion with the host cell membrane. Significantly, the ENV glycoprotein is the 
only target for neutralizing antibodies (Ward and Wilson, 2015). 
 A second structural gene is GAG, which encodes a main protein of HIV-1 involved in 
particle packaging. As a polyprotein, GAG contains three conserved domains: a matrix (MA), 
capsid (CA), and nucleocapsid (NC). GAG plays a major role in the assembly of virion particles 
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through GAG-GAG, GAG-membrane, and GAG-RNA interactions. Furthermore, the production 
of virion particles produced is dependent on the level of GAG expressed. Finally, packaging 
assembly requires recognition of HIV-1 RNA by HIV-1 GAG polyprotein. This is dependent on 
the presence of a packaging signal within the HIV-1 genome (Dilley et al., 2017). 
 The final identified key structural gene is POL, which encodes proteins involved in 
replication including protease (PR), integrase (IN), and reverse transcriptase (RT) (Nagata et al., 
2017). HIV-1 PR plays a primary role in cleaving HIV-1 polyproteins to form mature proteins 
and produce more virion particles (Rögnvaldsson et al., 2015). HIV-1 RT is responsible for the 
conversion of HIV-1 single-stranded RNA into double-stranded DNA form (Sluis-Cremer et al., 
2004). Formulating treatments to target these proteins may be challenging due to the high 
incidence of amino acid variability within each of these proteins (Rhee et al., 2016). 
 Six additional genes encode associated, supporting proteins. Of these six, two regulatory 
proteins are encoded by TAT and REV. A recent study on the role of TAT revealed its strong 
immunosuppressive qualities and ability to cross the blood-brain barrier (BBB). Additionally, 
TAT was shown to terminate the apoptosis pathways through induced expression of Bcl-2 
protein. Significantly, increased expression of Bcl-2 offers an additional way to inhibit apoptosis 
apart from suppressing caspase-3. Furthermore, TAT inhibits CD4+ and CD8+ maturation 
through the interruption of specific cytokine expression within the T cells (Karampoor et al., 
2020). HIV-1 REV also plays a regulatory role in the nuclear export of unspliced and partially 
spliced transcripts. Binding to a 351-nucleotide region identified as the REV response element 
(RRE), REV tags the viral transcripts with nuclear export factor Crm1. The export of these 
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transcripts is necessary for the formation of viral particles and production of structural proteins 
(Watts et al., 2018). 
 The accessory proteins encoded by NEF, VIF, VPU, and VPR are important in the 
infection process of HIV-1. During this process, the protein NEF targets host transmembrane 
proteins SERINC5 and SERINC3 and redirects them to a Rab7-positive endosomal 
compartment. This prevents SERINC5 and SERINC3  incorporation into virion particles, which 
normally disables particle entry into additional host cells (Rosa et al., 2015).  
 Identified as an intrinsically disordered protein (IDP), VIF is essential for viral 
replication in non-permissive cells. In the absence of VIF, APOBEC3G antiviral protein and 
other members of the APOBEC family may be incorporated in the HIV-1 virions, where they 
function as cytidine deaminases. Here, they replace cytidines (C) with uridines (U) in the reverse 
transcript strands. These mutations then translate from guanosines (G) to adenosines (A) in the 
transcribed double-stranded DNA, forming hypermutations. VIF binds to antiviral proteins of the 
APOBEC family to prevent this viral genome replication disruption through hypermutations.  
(Chan et al., 2018; Goila-Gaur and Strebel, 2008; Malim, 2006). 
 VPU plays a major role in the downregulation of host cell proteins, including T cell 
immunoglobulin and mucin domain-containing protein (Tim-3) (Cole and Sharpe, 2019; Prévost 
et al., 2020). Furthermore, VPR is required for replication in macrophages and has been 
demonstrated to accelerate viral replication. VPR contributes to the progression of HIV-1 
infection and impacts the host cell in a variety of ways, including negative alteration of the host 
cell’s energy metabolism, oxidation, and proteasome activities (González, 2017). 
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Figure 1. HIV-1 Encoded Proteins. 
The organization of the HIV-1 genome and the expression of HIV-1 proteins are pictured. 
Primary structural proteins include GAG, POL, and ENV. Accessory proteins include VIF, VPR, 
VPU, and NEF, while regulatory proteins include REV and TAT. A, pictured is the 5’ to 3’ 
reading frame for all major structural, accessory, and regulatory proteins encoded in DNA form. 
B, shown here is the HIV-1 genome in RNA form, requiring reverse-transcriptase activity.        
C, shown here are the transcripts for HIV-1 proteins which are either RRE-REV independent or 
dependent. Starring represents where splicing occurs. Figure obtained from  Kirchhoff, Frank et 
al., 2018. 
Cell Types and Receptors Targeted by HIV 
 The immune system constitutes an irreplaceable defense system within the body to 
combat infection and disease. As its name implies, HIV greatly impairs the immune system. The 
discovery of the viral genome being stored in the form of RNA rather than DNA led to the 
classification of HIV as a retrovirus. Previously, the only virus known to be a retrovirus was 
human T-cell lymphotropic virus I (HTLV-1). Thus, this was a significant discovery (Owen et 
al., 2013, p. 608).  
A 
B 
C 
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 As a retrovirus, HIV-1  primarily targets CD4 receptors on T lymphocytes upon entry to 
the body (Doitsh and Greene, 2016). CD4+ T cells constitute approximately 65% of the T cell 
population, while CD8+ T cells form the remainder (Ma et al., 2018). Comprised of four 
immunoglobulin-like domains and one ectodomain, the CD4 receptor is vital in the activation 
process of T cells. However, CD4 receptors also negatively contribute to HIV-1 infection (Chen, 
2019). Additional targeting of monocytes and macrophages with CD68+ receptors occurs within 
the spleen, liver, brain, lungs, bone marrow, and lymph nodes. Dendritic cells within lymphoid 
geminal centers and upon lymphoepithelial surfaces are also susceptible to HIV targeting (Lucas 
and Nelson, 2015).  
 Targeting occurs in the fusion process, whereby the virus enters the host cell. The process 
involves the approach of two membranes and subsequent overcoming of kinetic barriers for 
fusion to successfully occur. In most cases of fusion, the HIV-1 envelope glycoprotein initiates 
virion and host cell membrane attachment and facilitates subsequent fusion. The glycoprotein’s 
interaction with the CD4 receptor and, at times, additional coreceptors CCR5 or CXCR4,  leads 
to entry of HIV into the host cell (Chen, 2019). 
Replicative Life Cycle of HIV within Host Cells  
 Proliferation of the HIV infection depends on successful integration of the viral genome 
into the cellular genome (See Figure 2). Following the fusion of the viral and cellular 
membranes, the virus is released into the cell’s cytoplasm. The invading RNA is then transcribed 
into DNA through the activity of viral reverse transcriptase. In order to pass through the nuclear 
pore complex (NPC) and into the nucleus, a pre-integration complex (PIC) containing the viral 
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DNA, viral integrase, and capsid proteins must first form. This entry into the nucleus is also 
dependent on the lymphocyte’s stage in the cell division cycle (Lusic and Siliciano, 2017). 
 Areas with greater gene concentration and activity are targeted for the integration of viral 
DNA into the normal genome. While many factors influence the positioning of the viral 
genome’s integration, the integration process depends primarily upon the performance of 
integrase, which is encoded by the POL gene and has a central catalytic core domain (CCD) that 
is highly conserved in retroviral integrase proteins. Integrase performs specific functions of viral 
DNA 3′-end processing and strand transfer reactions. Additional influencers include sequence 
specificity, chromatin structure, and cellular tethering factors (Lusic and Siliciano, 2017). 
  The viral invasion is directed towards lymphocytes with permissive nuclear 
environments rather than nuclear environments in a resting state. In resting CD4+ T cells, the 
viral genome undergoes transcriptional silencing after integration. This creates a latent viral 
reservoir in inactivated cells, which contributes to the challenge of eradication. Currently, the 
process of viral integration into the host genome remains the only step within the nucleus that 
may be targeted and inhibited by pharmacological treatment.  A better understanding of the 
mechanism of viral integration could potentially lead to treatment improved in effectiveness and 
efficiency (Lusic and Siliciano, 2017).  
 Following integration, transcription of the viral genome requires the binding of TAT to 
the transacting response (TAR) element. TAT initiates the transcription of full-length HIV-1 
transcripts, as well as over 25 additional mRNAs produced from splicing. These splicing 
variations encode additional HIV proteins required for the spread of infection. The transcription 
of the viral genome allows for the export of RNA transcript from the nucleus, where translation 
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occurs and new virion particles may be assembled, packaged, and released to infect additional 
host cells (Kirchhoff, Frank et al., 2018). 
                            
Figure 2. HIV-1 Replicative Life Cycle. 
The replicative life cycle of HIV-1 involves multiple stages and relies on protein formation and 
activity. The virus enters the host cell by binding chemoreceptors CCR5 or CXCR4 (not 
pictured). Fusion of the virus membrane with host cell membrane leads to viral entry and 
subsequent replication and infection through the stages of reverse transcription activity, nuclear 
import, integration, transcription, RNA export, translation, assembly, budding, and maturation. 
Figure obtained from Kirchhoff, Frank et al., 2018. 
Host Cell Response 
The cellular response initiated upon HIV infection depends on the location and state of 
the CD4 T lymphocytes. Two primary modes of cellular response leading to programmed cell 
death have been identified: apoptosis initiated by caspase-3 and pyroptosis initiated by caspase-2 
(See Fig. 3). Apoptosis occurs in permissive CD4 T lymphocytes, which constitute 5% of the 
CD4 T lymphocyte population. In contrast, pyroptosis, a more intense form of programmed cell 
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death leading to inflammation, occurs in the resting, nonpermissive CD4 T lymphocytes, which 
comprise approximately 95% of the CD4 T lymphocyte density (Doitsh & Greene, 2016).  
The cellular responses of apoptosis and pyroptosis lead to a drastic reduction of T 
lymphocytes. Significantly, this depletion of CD4 T lymphocytes has been identified as the 
causative link to the progression towards acquired immune deficiency syndrome (AIDS) (Ma et 
al., 2018). Notably, however, the pathway of pyroptosis cannot occur in all resting CD4 T 
lymphocytes, specifically those circulating in the blood. In this case, the virus remains in the 
dormant lymphocytes, causing the viral load to increase over time (Doitsh & Greene, 2016). 
 
Figure 3. Side-by-Side Comparison of Cellular Death in Non-Permissive and Permissive 
CD4 T cells. 
Pictured are the two alternative pathways for host cell response. In infected non-permissive CD4 
T cells, caspase-1 is activated, initiating pyroptosis. In contrast, caspase-3 is activated, initiating 
apoptosis in infected permissive CD4 T cells. Figure obtained from Doitsh & Greene, 2016. 
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Clinical Presentation 
Medical Indications and Symptoms 
The progression of HIV infection occurs in three main stages. The acute or primary stage 
begins immediately after infection. As the infection spreads, the viral load, or number of virions, 
rapidly increases. During this stage, the anti-HIV-1 antibodies are not yet detectable, as 
seroconversion may take months to develop. Within 2 to 4 weeks of exposure, infected 
individuals may experience flu-like symptoms. Lymphadenopathy and overall malaise are 
common as well (Owen et al., 2013). 
As the infection progresses into the second stage, an asymptomatic period occurs. While 
the individual may experience no outward symptoms, a vicious internal response is occurring. 
The immune system activates antibodies and cytotoxic CD8+ T lymphocytes that help combat 
viral replication and reduce the viral load. However, a gradual decline in CD4+ T cells persists. 
Furthermore, the high replication rate of virus in infected CD4+ T cells continues, causing up to 
109 virions to be released per day. Over time, the rate of viral replication and virion release 
combined with persistent CD4+ depletion may overcome the immune system’s defense. The set 
point, measured by the level of viral load 6 months after infection, is often an indicator of the 
virus’s progression and an individual’s prognosis. 
Entry into the third stage indicates the progression to AIDS. This occurs in most cases 
where HIV-1 goes untreated. The diagnosis of AIDS requires the meeting of four criteria. First, 
antibodies or viral RNA are detected in the blood, indicating HIV-1 infection. Second, low 
concentrations of CD4+ T cells (<200 cells/ul of blood) are measured. Following these two 
factors, infected individuals may experience delayed or diminished immune responses to other 
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infections. Finally, the individuals may develop certain opportunistic infections, such as a 
Candida albicans infection, characterized by mouth sores; vulvovaginal yeast infection, 
experienced by women; or Pneumocystis carinii infection in the lungs, identified by a hacking 
cough. Entry into late-stage AIDS may lead to infections such as tuberculosis, pneumonia, or 
severe wasting diarrhea.  
HIV-Associated Disease Complications 
 HIV-associated psoriasis. Skin disorders are also commonly experienced by individuals 
infected with HIV. One such disorder is psoriasis, which is a chronic autoimmune disease that 
causes skin inflammation. The severity of psoriasis may range from mild to extremely severe and 
often corresponds to the degree of immunosuppression. Symptoms of psoriasis are often 
presented in a clinical dermatological setting and may indicate the onset of HIV (Ceccarelli et 
al., 2019). 
 Psoriasis may present in numerous forms. This includes plaque psoriasis, nail psoriasis, 
guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, and rupioid 
psoriasis. Of these variations, inverse psoriasis, or sebopsoriasis, is the most common in HIV-
infected populations. Lesions, appearing greasy and crusty, are mainly found under the armpits, 
around the breasts, and in the groin and genital area. Guttate psoriasis is another common form 
and appears primarily in children and young adults. Affected skin is normally in the region of the 
arms, legs, scalp, and trunk in the form of small droplet-shaped scaly lesions. The third most 
prevalent form in people with HIV is erythrodermic psoriasis. Characterizations of this type 
include desquamate areas of skin as well as itching and burning (Ceccarelli et al., 2019). 
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 While the exact mechanism by which HIV infection triggers psoriasis remains unknown, 
a correlation between increased severity of psoriasis inflammation and decreased concentration 
of CD4+ T cells is suspected. In cases of HIV infection, CD4+ T helper 1 (Th1) cells are 
activated. Cells are also stimulated to secrete interleukin (IL)-23, IL-12, interferon (IFN) gamma 
and tumor necrosis factor (TNF) alpha. As the level of CD4+ T cells decreases, the ratio of CD4+ 
to CD8+ T cells becomes significantly unbalanced. As such, CD8+ T cells, specifically memory 
CD8+ T cells, are thought to majorly contribute to the formation of skin lesions through their 
large presence in dermis and epidermis of these lesions and stimulation of pro-inflammatory 
cytokines, such as IL-17, IL-22, IFN gamma, and TNF alpha. Significantly, this has also been 
linked to triggering keratinocyte proliferation. Additional studies indicate instances where HIV-
encoded Nef protein functions as a superantigen, while other studies suggest that HIV-encoded 
Tat directly stimulates epidermal and endothelial cell production (Ceccarelli et al., 2019). 
 Treatment for this disease complication requires a non-traditional approach, as 
conventional treatments involving immunosuppressants must be avoided as much as possible. In 
the mild to moderate cases of psoriasis, combined antiretroviral treatment (cART) has proven 
effective. This involves the use of topical medications such as calcipotriene, corticosteroids, and 
tazarotene in conjunction with ART. In moderate to severe cases, ultraviolet radiation (UV) is 
used as a first line treatment option, while oral retinoids are used as a second line alternative 
(Ceccarelli et al., 2019). 
HIV-associated sensory neuropathy. As time has progressed, HIV-associated sensory 
neuropathy (HIV-SN) has been observed as a frequent disease complication in HIV-infected 
populations. Significantly, 30-60% of HIV-infected people experience this. HIV-SN is 
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characterized by pain originating in the distal lower extremities, which may radiate throughout 
the body to more proximal areas. In more severe cases, the upper extremities may also be 
affected. Individuals with HIV-SN have also noted fatigue, sleep disturbance, and depression due 
to chronic pain. As this pain is hard to assuage, affected individuals often experience negative 
changes in their quality of life (Kuo et al., 2019). 
This chronic condition is thought to have two possible causes. First, distal axonal 
degeneration is thought to be caused by the HIV-encoded glycoprotein gp120. In one 
investigation of the link between HIV-1 and infection-induced neuropathy, gp120 was 
demonstrated to significantly damage sensory axons. Axonal damage could occur via two 
separate pathways: cell apoptosis in the cell body compartment and local caspase activation in 
the axon. In addition, it was determined that 63% of axons exhibited the chemokine CCR5 
receptor while 94% expressed the CXCR4 receptor. Further testing revealed the presence of 
these receptors on axons enabled gp-120 binding, which caused axonal damage. The second 
possible cause of axonal damage has been linked to the antiretroviral agents. ART specifically 
involving viral reverse-transcriptase inhibitors is suspected to unintentionally induce damage in 
axons. In the conclusion of the study, the development of chemokine inhibitors to prevent initial 
HIV entry were suggested as a potential aid in combatting the effects of HIV-1 in its progression 
towards AIDS (Melli et al., 2006).  
Diagnosis 
 Over time, diagnostic techniques have increased in sophistication and sensitivity. 
Diagnosis techniques include PCR or viral load, P24 test, first/second/third generation Antibody 
(Ab) tests, fourth generation Antibody/Antigen (Ab/Ag) tests, Western blot tests, and rapid 
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testing through capillary blood, urine, or oral secretion samples (See Table 1). With advancement 
of diagnostic techniques and equipment, the HIV antibody can now be detected within only one 
to two weeks after infection. However, the P24 test may be used to detect P24 antigenic protein, 
a protein produced by HIV GAG gene that forms a major part of  the viral core, and confirm HIV 
infection before antibodies become detectable (Bystryak and Acharya, 2016; Zulfiqar et al., 
2017). Circumstances, accessibility, and timeframe factors all contribute to the specific test used 
for each patient. An early diagnosis is pertinent for prevention of further transmission and the 
effectiveness of ART treatment. 
Table 1. Tests used in the Diagnosis of HIV-1.  
Listed above are different tests used in the diagnosis of HIV-1. Tests involving the detection of 
antibodies are most commonly used. Tests may be chosen based on availability, timeframe and 
economic factors, and the specific needs of each patient. Table data obtained from Zulfiqar et al., 
2017. 
Treatment with Antiretroviral Therapy 
 Since the discovery of HIV around forty years ago, treatment options have dramatically 
improved. Currently, the best treatment option exists in the form of antiretroviral therapy, which 
Type of Test Detection of 
DNA/RNA 
Detection of 
Antigen 
Detection of 
Antibody 
    
PCR or viral load Y N N 
P24 test N Y N 
4th generation Ag/Ab tests N Y N 
Duo, Combo/Combi, etc. Y Y Y 
1st/2nd/3rd generation tests N N Y 
Rapid tests (finger prick/oral swab) N N Y 
Western blots look for Ab to specific HIV proteins N N Y 
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exists as a combination therapy. The standard combination includes three substances: two 
nucleoside reverse transcriptase inhibitors (NRTI) with an integrase inhibitor (INI), boosted 
protease inhibitor (PI), non-nucleoside reverse transcriptase inhibitor (NNTRI), or entry 
inhibitor. NRTIs effectively inhibit viral reverse transcriptase proteins and prevent the translation 
of single-stranded RNA into proviral double-stranded DNA. Abacavir or tenofovir are normally 
chosen as the first NRTI, with indistinguishable differences in efficacy. However, abacavir may 
only be administered in cases where human leukocyte antigen HLA-B 5701 is negative in order 
to prevent occurrences of hypersensitivity reaction, while tenofovir is the favored choice in the 
presence of hepatitis B. Lamivudine (3TC) or emtricitabine (FTC) is normally selected as the 
second NRTI. No significant differences in efficacy have been detected (Lehmann et al., 2019). 
 Typically recommended as the third substance, an integrase inhibitor prevents the 
insertion of viral DNA into the human genome within host cells. Alternatively, PI prevents HIV 
protease from producing cleaved subunits of GAG-POL protein and thereby impedes the 
production of viral-containing particles. Another alternative would include a NNRTI, which 
functions similarly to NRTIs. Finally, entry inhibitors may be used in the combination of ART. 
Entry inhibitors may function in a variety of ways, depending on the type used. This includes 
types that prevent viral entry by coating protein gp120 and CD4 receptor, binding coreceptors 
CCR5 or CXCR4, or fusing the virus and cell with the subcutaneously administered fusion 
inhibitor enfuvirtide.  Proper drug selection for combination therapy is important for maximized 
effectiveness. Once the right combination has been determined, patients may acquire their 
treatment in pill-form to be taken once daily (Lehmann et al., 2019). 
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 Concern over increased side effects has raised the question of when to begin ART 
treatment. Subsequent studies have revealed the importance and added benefits of initiating ART 
early rather than delaying it. Thus, it is recommended that ART is started within a few weeks 
after testing positive for HIV. This should be preceded by a resistance test to anticipate viral-
induced drug resistance and ensure ART effectiveness. Comorbidities must also be considered in 
the selection of combination drugs, especially as patients age over time. Additionally, ART 
requires the consultation of highly experienced experts in cases of pregnancy (Lehmann et al., 
2019). 
 ART combination drugs may require re-evaluation in the case of virological failure, 
where levels of HIV-RNA are repeatedly measured to be over 200 copies/ml in the blood. 
However, other factors must also be taken into account, including the patient’s adherence to 
ART, other medications taken simultaneously, drug resistance, or the presence of concomitant 
diseases (Lehmann et al., 2019). 
 While a treatment that fully eradicates HIV has not yet been discovered, long-term 
treatment in the form of ART has been demonstrated as an effective alternative. ART 
specifically prevents opportunistic infections, premature death, and further transmission of the 
virus. Additionally, the risk of perinatal transmission is reduced to 1% after treatment is initiated 
in a pregnant mother (Lehmann et al., 2019). 
 Novel research indicates the possibility of shifting to a two-drug regimen instead of the 
traditional three-drug combination in current ART. Scientific evidence gained from multiple 
studies shows improved levels of tolerability, lower toxicity, and greater viral suppression. 
Furthermore, the dual drug model reduces risks of cardiovascular disease as well as bone and 
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renal toxicities. Additionally, this treatment alteration reduces therapy costs and thus expands the 
availability of treatment to more people. Within the US, an estimate of between 500 million and 
3 billion dollars would be saved in ART costs in the span of five years if two antiretroviral drugs 
rather than three were used to treat HIV patients. Internationally, the cost differential would have 
even more significance. Already, certain international standards have adopted the dual drug 
therapy option, whose simplified yet effective regimen includes an integrase inhibitor with 
elevated levels of inhibitor and reverse transcriptase inhibitor (Duarte and Soares, 2019). 
Opioid Crisis in HIV Patients 
Additional research has uncovered the major effect opioids such as morphine and heroin 
have on the immune system, particularly on the enhancement of HIV-1 infection. This research 
was stimulated by consideration of the overlap between the HIV-1 epidemic and the opioid 
crisis. Since then, numerous research studies have been performed that demonstrate the 
immunosuppressant properties of opioids and identify the specific effects of opioids on the 
enhancement of HIV-1 infection (Eisenstein, 2019).  
Opioid Receptors 
 Three major opioid receptors have been identified: mu opioid receptor (MOR), kappa 
opioid receptor (KOR), and delta opioid receptor (DOR). Additionally, the ligands which bind to 
these receptors have been identified as the neuropeptides beta-endorphin (MOR), dynorphin 
(KOR), and methionine-enkephalin (DOR) (Eisenstein, 2019). These opioid receptors are 
expressed in the central nervous system (CNS) and on the surfaces of many cells within the 
immune system (Steele et al., 2003). Morphine and heroin have been shown to have the greatest 
binding affinity for the MOR, inducing intracellular receptor signaling (Eisenstein, 2019).  
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Major Opioids Receptor Agonists and Antagonists 
 Study of the immunological effects of opioids first requires adequate understanding of 
the opioids themselves. Derived from the opioid poppy plant, morphine is an alkaloid which has 
a high binding affinity for MOR. The effects of this drug have been studied in human and murine 
models, both in vitro and in vivo. A similar though synthetic version of morphine is heroin, 
which contains diacetyl, but is metabolized to morphine. Major opioid antagonists include 
naloxone and naltrexone, which bind to all three opioid receptors. A third major opioid 
antagonist is beta-funaltrexamine (beta-FNA), which binds selectively to MOR. As the 
commercially-sold version of naloxone, Narcan® has a greater affinity for MOR than morphine, 
and can mitigate morphine-induced effects upon binding without stimulating receptor signaling 
(Eisenstein, 2019). 
Opioid Enhancement of HIV Infection 
Increased CXCR4 and CCR5 expression. One research study demonstrated enhanced 
CXCR4 and CCR5 expression as a result of opioid exposure. In the study, CD14+ monocytes and 
CD3+ lymphoblasts were exposed to DAMGO, which is a highly specific MOR agonist with the 
ability to simulate the effect of morphine. Testing revealed increased levels of CXCR4 and 
CCR5 receptors on the cell surfaces. However, this was only observed in activated T cells, while 
significant change was not detectable in resting cells (Steele et al., 2003). A similar effect of 
CCR5 upregulation in macrophages and CXCR4 and CCR5 upregulation in astrocytes was 
observed. This correlation of opioid exposure and CXC4 and CCR5 upregulation is significant, 
as these coreceptors are required for HIV-1 binding and fusion with a host cell.(Eisenstein, 
2019).  
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Increased p24 levels. Further testing of HIV-1 cells exposed to DAMGO revealed 
increased levels of HIV-1 p24 antigen. Similar results were also observed in HIV-1 cells exposed 
to morphine. This further confirmed the causative link between opioids and the enhancement of  
HIV-1 infection (Steele et al., 2003). 
Downregulation of antiviral miRNA. In addition, morphine and heroin have been shown 
to negatively impact antiviral innate immunity defenses against HIV-1 infection in macrophages. 
Within macrophages, restriction microRNAs (miRNAs) are expressed which target parts of the 
HIV-1 genome and inhibit translation of key HIV-1 proteins, including TAT and REV. 
Specifically, miRNA-28, miRNA-125b, miRNA-150, miRNA-223, and miRNA-382 perform 
these inhibitory functions and help impede HIV-1 infection. Significantly, these miRNAs are 
also often plentiful in resting CD4+ T cells and monocytes, and are often expressed in response 
to IFN-alpha/beta signaling. However, a decrease in miRNA expression was observed in 
macrophages treated with heroin. Specifically, downregulation of miRNA-28, miRNA-125b, 
miRNA-150, and miRNA-382 were detected (Wang et al., 2015). 
Suppression of IFN-alpha/beta and suppression of cytokine production. Additionally, 
heroin was shown to suppress IFN-alpha and IFN-beta expression in macrophages. Heroin-
induced suppression of IFN-alpha/beta may be a causative link to reduced levels of miRNA 
expression, as IFN-alpha/beta stimulates miRNA expression (Wang et al., 2015).  Furthermore, 
in HIV-infected cells treated with heroin, the downregulation of cytokine production was 
observed. Specifically, significantly reduced levels of IL-1 β, IL-6, IFN-γ, and TNF-α were 
detected (Meijerink et al., 2015). 
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Opioid Management 
 The need for improved management of treatment with opioids has gained awareness in 
recent years. Within the HIV- infected population, chronic pain is more commonly experienced 
and treated with opioids. However, long-term prescription of opioids for chronic pain may 
increase the risk of opioid abuse disorder. In addition, those infected with HIV are often more 
likely to have substance use disorders and mental illness, which further increases opioid abuse 
risks. This situation demands increasing awareness, attention, and action (Cunningham, 2018). 
Chronic opioid therapy has been identified as a main cause of the opioid crisis (Carroll et 
al., 2019). Data from the Centers for Disease Control and Prevention (CDC) reveal that over 
70,000 people died in 2017 due to drug overdoses. Significantly, approximately 68% of these 
deaths were linked to opioids obtained illicitly or via prescription (CDC, 2019). Further research 
is needed regarding how many of these overdoses were linked to HIV patients receiving opioid 
treatment for chronic pain. Nevertheless, in seeking to lower such devastating statistics, opioid 
management must improve. However, this is undeniably complex, and involves the role and 
responsibility of the HIV-infected individual as well as the HIV clinician and healthcare system.  
In a recent study, multiple physicians were interviewed regarding their experience in and 
knowledge of chronic pain management in HIV-infected individuals. This study revealed that 
clinicians felt a lack of confidence and knowledge about safe opioid prescription management. 
Clinicians stated they had little previous experience regarding this. Furthermore, clinicians were 
concerned about straining clinician-patient relationships in their attempts to better monitor opioid 
usage and results. Clinicians emphasized the importance of having a trusting relationship with 
the patient to ensure successful HIV monitoring. Additionally, clinicians feared that patient 
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retention would be negatively affected. Finally, clinicians voiced concern over increased volume 
of administrative tasks if opioid monitoring protocol were to increased (Carroll et al., 2019). 
The study offered solutions, many of which were enthusiastically received by the 
concerned clinicians (See Table 2). This included offering more academic sessions which better 
informed clinicians on how to properly and safely manage opioid prescriptions. An increase in 
support staff was also suggested and well received. Finally, the solution to train and hire more 
addiction specialists was also approved by clinicians (Carroll et al., 2019). 
Initiating Treatment with 
Opioids 
Determining Opioid Selection, 
Dose, Duration, Follow-up, and 
Discontinuation 
Assessing Risks and Harms of 
Treatment with Opioids 
Nonpharmacologic and 
nonopioid therapies are preferred 
Establish treatment goals (pain 
and function levels) 
Discuss risks and benefits of 
opioid use and patient and 
practitioner responsibilities 
Prescribe immediate-release (not 
long-acting) formulations 
Prescribe lowest effective opioid 
dose (<50–90 morphine milligram 
equivalent) 
Prescribe no greater quantity than 
needed (enough for ≤3–7 days) 
Reevaluate effectiveness. If risk or 
harms are substantial, taper or 
discontinue 
Evaluate and mitigate harms 
 Consider naloxone 
Use a prescription drug monitoring 
program 
Order urine toxicology tests 
Avoid concurrent use of opioids 
and benzodiazepines 
Offer buprenorphine or methadone 
to treat opioid use disorder 
 
Table 2. CDC Guidelines for Centers Prescribing Opioids for Non-Cancer-Related Chronic 
Pain. 
The CDC guidelines provide a framework to reform approaches to prescribing and treating with 
opioids. Data obtained from (Cunningham, 2018). 
Conclusion 
 In conclusion, human immunodeficiency virus, also known as HIV, is a devastating 
disease which has affected and still affects millions globally. While many cases of HIV exist in 
the United States, HIV is most prevalent in sub-Saharan Africa (Williams et al., 2017). While 
HIV may be identified as type 1 or type 2, type 1 has been diagnosed globally, while type 2 is 
restricted to specific areas of the globe (Vidya Vijayan et al., 2017). Numerous studies have been 
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conducted that detail the viral genome and reveal the molecular mechanisms by which the virus 
enters and infects host cells. HIV is a retrovirus which encodes its genome in the form of RNA. 
Infection occurs primarily in CD4+ T cells, which normally possess coreceptors CCR4 or 
CXCR5. Once in the host cell, the viral genome is replicated and integrated into the host cell 
genome. In activated CD4+ T cells, the entry and attack of HIV leads to a drastic host cell 
response, often resulting in apoptosis. However, in resting CD4+ T cells, the viral genome may 
remain integrated and intact in the host cell for a later attack (Doitsh and Greene, 2016). 
 A significant reduction of CD4+ T cells often occurs before an individual is aware of 
infection. Within 2-4 weeks of infection, individuals may experience flu-like symptoms. As the 
disease develops, symptoms increase in severity (Owen et al., 2013). The progression of HIV 
often involves the development of disease complications, including different varieties of HIV-
associated psoriasis and sensory neuropathy (Ceccarelli et al., 2019; Melli et al., 2006). 
Currently, the most effective treatment option exists in the form of ART, which involves the 
strategically chosen combination of three drugs that function to inhibit HIV-encoded proteins. 
Most commonly, two nucleoside reverse-transcriptase inhibitor are used in conjunction with an 
integrase inhibitor. While ART fails to eradicate the virus, it has demonstrated high levels of 
efficacy in combatting the virus (Lehmann et al., 2019). 
 In addition to ART, opioids are commonly prescribed to people living with HIV to 
combat chronic pain experienced on a daily basis. However, extensive research studies have 
demonstrated the immunosuppressant properties of opioids such as heroin and morphine. 
Significantly, the intersection of the HIV epidemic and opioid crisis requires the attention of 
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researchers and clinicians. Additionally, clinicians, especially those who prescribe medication, 
must be adequately informed and properly equipped to address these complicated factors. 
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